ArticleVirologica Sinica2020
The Establishment of Infectious Clone and Single Round Infectious Particles for Coxsackievirus A10.
Article in Virologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Screening of Insertion Sites and Tags on EV-A71 VP1 Protein for Recombinant Virus Construction.Viruses · 2025Article
- The nucleoside analog 4'-fluorouridine suppresses the replication of multiple enteroviruses by targeting 3D polymerase.Antimicrobial agents and chemotherapy · 2024Article
- Integration of HiBiT into enteroviruses: A universal tool for advancing enterovirus virology research.Virologica Sinica · 2024Article
- Construction of an infectious clone for enterovirus A89 and mutagenesis analysis of viral infection and cell binding.Microbiology spectrum · 2024Article
- Construction and characterization of an infectious cDNA clone of human rhinovirus A89.Heliyon · 2024Article
- VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice.PLoS pathogens · 2023Article
- Construction of coxsackievirus B5 viruses with luciferase reporters and their applications in vitro and in vivo.Virologica Sinica · 2023Article
- Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.Virus research · 2023Article
- A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection.Current research in microbial sciences · 2023Article
- Construction and verification of an infectious cDNA clone of coxsackievirus B5.Virologica Sinica · 2022Article
- Reverse Genetic Approaches for the Generation of Full Length and Subgenomic Replicon of EV71 Virus.Frontiers in microbiology · 2021Article
- Rules governing genetic exchanges among viral types from differentThe Journal of general virology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus A10 (CVA10) is one of the major etiological agents of hand, foot, and mouth disease. There are no vaccine and antiviral drugs for controlling CVA10 infection. Reverse genetic tools for CVA10 will benefit its mechanistic study and development of vaccines and antivirals. Here, two infectious clones for the prototype and a Myc-tagged CVA10 were constructed. Viable CVA10 viruses were harvested by transfecting the viral mRNA into human rhabdomyosarcoma (RD) cells. Rescued CVA10 was further confirmed by next generation sequencing and characterized experimentally. We also constructed the vectors for CVA10 subgenomic replicon with luciferase reporter and viral capsid with EGFP reporter, respectively. Co-transfection of the viral replicon RNA and capsid expresser in human embryonic kidney 293T (HEK293T) cells led to the production of single round infectious particles (SRIPs). Based on CVA10 replicon RNA, SRIPs with either the enterovirus A71 (EVA71) capsid or the CVA10 capsid were generated. Infection by EVA71 SRIPs required SCARB2, while CVA10 SRIPs did not. Finally, we showed great improvement of the replicon activity and SRIPs production by insertion of a cis-active hammerhead ribozyme (HHRib) before the 5'-untranslated region (UTR). In summary, reverse genetic tools for prototype strain of CVA10, including both the infectious clone and the SRIPs system, were successfully established. These tools will facilitate the basic and translational study of CVA10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.